Medically appropriate responses include dose reduction, temporary pause for symptom assessment, slower re-escalation, or consideration of alternative GLP-1 agonists or formulations that may carry lower neurological burden for that individual
The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects
In Parkinsons, symptoms result from a slight decrease in cells in the middle of the brain
Beverages with high alcohol content can also slow down stomach emptying, which can worsen symptoms while on Wegovy
Although not a direct drug-drug interaction, increased GH/IGF-1 levels may raise blood glucose
In fibroblast models, researchers observed that GHK-Cu is associated with increased collagen type I and III synthesis, fibronectin production, and glycosaminoglycan deposition
